ArticleDiagnostic pathology2022

Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively.

Hong Tao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.